Brief: Crism Therapeutics Provides Update On Phase 2 Clinical Trial Of Irinotecan-Chemoseed In Glioblastoma
25/03/2026 07:37
March 25 (Reuters) - CRISM' Therapeutics Corp CRTX.L: CRISM THERAPEUTICS - PHASE 2 CLINICAL TRIAL PROGRESS UPDATE CRISM' THERAPEUTICS CORP - CRISM EXTENDS GUIDANCE ON FIRST PATIENT DOSING TO H1 2026 Source text: ID:nRSY9592Xa Further company coverage: CRTX.L ((Reuters.Briefs@thomsonreuters.com))